541 related articles for article (PubMed ID: 25330774)
1. The major cystic fibrosis causing mutation exhibits defective propensity for phosphorylation.
Pasyk S; Molinski S; Ahmadi S; Ramjeesingh M; Huan LJ; Chin S; Du K; Yeger H; Taylor P; Moran MF; Bear CE
Proteomics; 2015 Jan; 15(2-3):447-61. PubMed ID: 25330774
[TBL] [Abstract][Full Text] [Related]
2. A chemical corrector modifies the channel function of F508del-CFTR.
Kim Chiaw P; Wellhauser L; Huan LJ; Ramjeesingh M; Bear CE
Mol Pharmacol; 2010 Sep; 78(3):411-8. PubMed ID: 20501743
[TBL] [Abstract][Full Text] [Related]
3. VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface.
Eckford PD; Ramjeesingh M; Molinski S; Pasyk S; Dekkers JF; Li C; Ahmadi S; Ip W; Chung TE; Du K; Yeger H; Beekman J; Gonska T; Bear CE
Chem Biol; 2014 May; 21(5):666-78. PubMed ID: 24726831
[TBL] [Abstract][Full Text] [Related]
4. Probing conformational rescue induced by a chemical corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant.
Yu W; Kim Chiaw P; Bear CE
J Biol Chem; 2011 Jul; 286(28):24714-25. PubMed ID: 21602569
[TBL] [Abstract][Full Text] [Related]
5. Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms.
Roxo-Rosa M; Xu Z; Schmidt A; Neto M; Cai Z; Soares CM; Sheppard DN; Amaral MD
Proc Natl Acad Sci U S A; 2006 Nov; 103(47):17891-6. PubMed ID: 17098864
[TBL] [Abstract][Full Text] [Related]
6. Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells.
Favia M; Mancini MT; Bezzerri V; Guerra L; Laselva O; Abbattiscianni AC; Debellis L; Reshkin SJ; Gambari R; Cabrini G; Casavola V
Am J Physiol Lung Cell Mol Physiol; 2014 Jul; 307(1):L48-61. PubMed ID: 24816489
[TBL] [Abstract][Full Text] [Related]
7. Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Chung WJ; Goeckeler-Fried JL; Havasi V; Chiang A; Rowe SM; Plyler ZE; Hong JS; Mazur M; Piazza GA; Keeton AB; White EL; Rasmussen L; Weissman AM; Denny RA; Brodsky JL; Sorscher EJ
PLoS One; 2016; 11(10):e0163615. PubMed ID: 27732613
[TBL] [Abstract][Full Text] [Related]
8. Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del.
Chin S; Hung M; Won A; Wu YS; Ahmadi S; Yang D; Elmallah S; Toutah K; Hamilton CM; Young RN; Viirre RD; Yip CM; Bear CE
Mol Pharmacol; 2018 Aug; 94(2):917-925. PubMed ID: 29903751
[TBL] [Abstract][Full Text] [Related]
9. The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domain.
Laselva O; Molinski S; Casavola V; Bear CE
Biochem Pharmacol; 2016 Nov; 119():85-92. PubMed ID: 27614011
[TBL] [Abstract][Full Text] [Related]
10. Correctors of mutant CFTR enhance subcortical cAMP-PKA signaling through modulating ezrin phosphorylation and cytoskeleton organization.
Abbattiscianni AC; Favia M; Mancini MT; Cardone RA; Guerra L; Monterisi S; Castellani S; Laselva O; Di Sole F; Conese M; Zaccolo M; Casavola V
J Cell Sci; 2016 Mar; 129(6):1128-40. PubMed ID: 26823603
[TBL] [Abstract][Full Text] [Related]
11. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1.
Ren HY; Grove DE; De La Rosa O; Houck SA; Sopha P; Van Goor F; Hoffman BJ; Cyr DM
Mol Biol Cell; 2013 Oct; 24(19):3016-24. PubMed ID: 23924900
[TBL] [Abstract][Full Text] [Related]
12. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation.
Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN
J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700
[TBL] [Abstract][Full Text] [Related]
13. Defective formation of PKA/CnA-dependent annexin 2-S100A10/CFTR complex in DeltaF508 cystic fibrosis cells.
Borthwick LA; Riemen C; Goddard C; Colledge WH; Mehta A; Gerke V; Muimo R
Cell Signal; 2008 Jun; 20(6):1073-83. PubMed ID: 18346874
[TBL] [Abstract][Full Text] [Related]
14. Insights into the mechanisms underlying CFTR channel activity, the molecular basis for cystic fibrosis and strategies for therapy.
Kim Chiaw P; Eckford PD; Bear CE
Essays Biochem; 2011 Sep; 50(1):233-48. PubMed ID: 21967060
[TBL] [Abstract][Full Text] [Related]
15. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
Amico G; Brandas C; Moran O; Baroni D
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
[TBL] [Abstract][Full Text] [Related]
16. A new 9-alkyladenine-cyclic methylglyoxal diadduct activates wt- and F508del-cystic fibrosis transmembrane conductance regulator (CFTR) in vitro and in vivo.
Boucherle B; Bertrand J; Maurin B; Renard BL; Fortuné A; Tremblier B; Becq F; Norez C; Décout JL
Eur J Med Chem; 2014 Aug; 83():455-65. PubMed ID: 24992073
[TBL] [Abstract][Full Text] [Related]
17. Differential thermostability and response to cystic fibrosis transmembrane conductance regulator potentiators of human and mouse F508del-CFTR.
Bose SJ; Bijvelds MJC; Wang Y; Liu J; Cai Z; Bot AGM; de Jonge HR; Sheppard DN
Am J Physiol Lung Cell Mol Physiol; 2019 Jul; 317(1):L71-L86. PubMed ID: 30969810
[TBL] [Abstract][Full Text] [Related]
18. Current insights into the role of PKA phosphorylation in CFTR channel activity and the pharmacological rescue of cystic fibrosis disease-causing mutants.
Chin S; Hung M; Bear CE
Cell Mol Life Sci; 2017 Jan; 74(1):57-66. PubMed ID: 27722768
[TBL] [Abstract][Full Text] [Related]
19. Deletion of phenylalanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels.
Wang F; Zeltwanger S; Hu S; Hwang TC
J Physiol; 2000 May; 524 Pt 3(Pt 3):637-48. PubMed ID: 10790148
[TBL] [Abstract][Full Text] [Related]
20. Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR.
Sampson HM; Robert R; Liao J; Matthes E; Carlile GW; Hanrahan JW; Thomas DY
Chem Biol; 2011 Feb; 18(2):231-42. PubMed ID: 21338920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
